Current evidence summary In 11 lactating women given 5 mg subcutaneous tirzepatide, 95.9 percent of milk samples showed undetectable levels
Common side effects and contraindications (bullet list): Mild injection-site redness, bruising Increased hunger, flushing, water retention Headache, dizziness, nausea Temporary joint discomfort Contraindications: active cancer, uncontrolled diabetes, pregnancy, certain cardiac conditions Long-Term Effects Long-term use of CJC-1295, either alone or in combination with peptides such as Ipamorelin, may cause persistent changes in hormones impacting reproductive health and aging
Drowsiness after injection is a normal and expected response
NICE guidelines (NG28) recommend GLP-1 receptor agonists for type 2 diabetes in specific circumstances, typically in combination with other treatments when certain criteria are met, including BMI thresholds